Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 42, Issue 3, 2014, Pages 901-908

  Antonell, Anna ^a   Mansilla, Alicia ^a   Rami, Lorena ^a   Lladó, Albert ^a   Iranzo, Alex ^a   Olives, Jaume ^a   Balasa, Mircea ^a   Sánchez Valle, Raquel ^a   Molinuevo, José Luis ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Alzheimer's disease; amyloid 42; cerebrospinal fluid; correlation; neuropsychological tests; preclinical; tau protein; YKL 40

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PHOSPHORYLATED TAU PROTEIN; PROTEIN; TAU PROTEIN; TOTAL TAU PROTEIN; UNCLASSIFIED DRUG; YKL 40 PROTEIN; ADIPOCYTOKINE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; CHI3L1 PROTEIN, HUMAN; LECTIN; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; ELISA KIT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PARASOMNIA; PRECLINICAL ALZHEIMER DISEASE; PRODROMAL ALZHEIMER DISEASE; PRODROMAL SYMPTOM; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; CEREBROSPINAL FLUID; GENETICS; MENTAL HEALTH; MIDDLE AGED; STATISTICS;

ADIPOKINES; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; FEMALE; HUMANS; LECTINS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PRODROMAL SYMPTOMS; STATISTICS AS TOPIC; TAU PROTEINS;

EID: 84907148177     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140624     Document Type: Article

References (35)

1. Rejman JJ, Hurley WL (1988) Isolation and characterization of a novel 39 kilodalton whey protein from bovine mammary secretions collected during the nonlactating period. Biochem Biophys Res Commun 150, 329-334.
2. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM,Quinn JF, D'Angelo G, Malone JP,Townsend RR, Morris JC, Fagan AM, HoltzmanDM(2010) YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68, 903-912.
3. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA(2010) In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 7, 34.
4. Choi J, LeeHW, SukK(2011) Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer's disease. J Neurol 258, 2181-2185.
5. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA (2006) Serum YKL-40, a new prognostic biomarker in cancer patients Cancer Epidemiol Biomarkers Prev 15, 194-202.
6. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA,Morris JC, Holtzman DM, Townsend RR, Fagan AM (2011) Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 6, e16032.
7. Braak H, Braak E (1997) Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 18, S85-S88.
8. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
9. Antonell A, Fortea J, Rami L, Bosch B, Balasa M, Sanchez-Valle R, Iranzo A, Molinuevo JL, Llado A (2011) Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm 118, 259-262.
10. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9, 1118-1127.
11. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
12. Iranzo A, Lomena F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, Molinuevo JL, Serradell M, Duch J, Pavia J, Gallego J, Seppi K, Hogl B, Tolosa E, Poewe W, Santamaria J (2010) Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study [corrected]. Lancet Neurol 9, 1070-1077.
13. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
14. Rami L, Sole-Padulles C, Fortea J, Bosch B, Llado A, Antonell A, Olives J, Castellvi M, Bartres-Faz D, Sanchez-Valle R, Molinuevo JL (2012) Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. Int J Geriatr Psychiatry 27, 127-134.
15. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
16. Rami L, Gomez-Anson B, Bosch B, Sanchez-Valle R, Monte GC,Villar A, Molinuevo JL (2007) Cortical brain metabolism as measured by proton spectroscopy is related to memory performance in patients with amnestic mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 24, 274-279.
17. Buschke H (1984) Cued recall in amnesia. J Clin Neuropsychol 6, 433-440.
18. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39, 1159-1165.
19. Aguirre-Acevedo DC, Gomez RD, Moreno S, Henao-Arboleda E, Motta M, Munoz C, Arana A, PinedaDA, Lopera F (2007) Validez y fiabilidad de la baterá neuropsicológica CERAD-Col. Rev Neurol 45, 655-660.
20. Garcá-Albea JE, Sánchez Bernardos L, del Viso-Pabón S (1986) Test de Boston para el diagnóstico de la afasia. Adaptación espanola. In La evaluacion de la afasia y de trastornos relacionados, Goodglass H, Kaplan E, eds.Médica Panamericana, Madrid, pp. 129-198.
21. Kaplan E, Goodglass H,Weintraub S (1983) The Boston Naming Test, Lea and Febiger, Philadelphia.
22. Warrington EK, James M. (1991) TheVisual Object and Space Perception Battery. Thames Valley Test Company, Bury St. Edmunds, UK.
23. Rami L, Serradell M, Bosch B,Villar A, Molinuevo JL (2007) [Perception Digital Test (PDT) for the assessment of incipient visual disorder in initial Alzheimer's disease]. Neurologia 22, 342-347.
24. Wechsler D (1999) Escala de inteligencia de Wechsler para adultos-III (WAIS III), TEA, Madrid.
25. Reitan RM (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Percep Mot Skills 8, 271-276.
26. Borkowski JG, Spreen BA, O (1967)Word fluency and brain damage. Neuropsychologia 5, 135-140.
27. Del Ser T, Gonzalez-Montalvo JI, Martinez-Espinosa S, Delgado-Villapalos C, Bermejo F (1997) Estimation of premorbid intelligence in Spanish people with the Word Accentuation Test and its application to the diagnosis of dementia. Brain Cogn 33, 343-356.
28. Olsson B, Hertze J, Lautner R, Zetterberg H, Nagga K, Hoglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Blennow K, Hansson O (2013) Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis 33, 45-53.
29. Molinuevo JL, Gispert JD, Dubois B, Heneka MT, Lleo A, Engelborghs S, Pujol J, de Souza LC, Alcolea D, Jessen F, Sarazin M, Lamari F, Balasa M, Antonell A, Rami L (2013) The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: A validation study. J Alzheimers Dis 36, 67-77.
30. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP (2006) Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 3, 27.
31. Miller KR, Streit WJ (2007) The effects of aging, injury and disease on microglial function:Acase for cellular senescence. Neuron Glia Biol 3, 245-253.
32. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12, 357-367.
33. ReisbergB, ShulmanMB,Torossian C, Leng L, ZhuW(2010) Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement 6, 11-24.
34. Jessen F,Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kolsch H, Luck T, Mosch E, van den Bussche H, Wagner M, Wollny A, Zimmermann T, Pentzek M, Riedel-Heller SG, Romberg HP, Weyerer S, Kaduszkiewicz H, Maier W, Bickel H (2010) Prediction of dementia by subjective memory impairment: Effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry 67, 414-422.
35. van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, van der Flier WM (2013) Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement 9, 481-487.